

Solomon Islands

Tuberculosis profile

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.057 (0.037–0.081)	9.8 (6.4–14)
Mortality (HIV+TB only)	0 (-)	0 (-)
Incidence (includes HIV+TB)	0.52 (0.4–0.65)	89 (69–112)
Incidence (HIV+TB only)		
Incidence (MDR/RR-TB)**	0.032 (0.019–0.045)	5.5 (3.3–7.7)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	<0.01 (0–<0.01)	0.26 (0.2–0.32)	0.26 (0.2–0.32)
Males	<0.01 (0–<0.01)	0.26 (0.2–0.32)	0.26 (0.2–0.32)
Total	<0.01 (<0.01–<0.01)	0.52 (0.45–0.58)	0.52 (0.4–0.65)

TB case notifications, 2015

Total cases notified	417
Total new and relapse	416
- % tested with rapid diagnostics at time of diagnosis	15%
- % with known HIV status	20%
- % pulmonary	61%
- % bacteriologically confirmed among pulmonary	68%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	80% (64–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.11 (0.07–0.17)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	1	1%
- on antiretroviral therapy	1	100%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			12 (7–18)
Estimated % of TB cases with MDR/RR-TB	5.2% (3.1–7.3)	0% (0–41)	
% notified tested for rifampicin resistance	14%	45%	64
MDR/RR-TB cases tested for resistance to second-line drugs		1	
Laboratory-confirmed cases		MDR/RR-TB: 1, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 1, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	91%	345
Previously treated cases, excluding relapse, registered in 2014	0%	1
HIV-positive TB cases, all types, registered in 2014		0
MDR/RR-TB cases started on second-line treatment in 2013		0
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	2.5% (2.3–2.8)

TB financing, 2016

National TB budget (US\$ millions)	1.3
Funding source: 16% domestic, 84% international, 0% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence


Notified (new and relapse)

Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New and relapse


Retreatment, excluding relapse

HIV-positive

MDR/RR-TB

XDR-TB

Total budget (US\$ millions)



Unfunded

Funded internationally

Funded domestically